Atlas Venture
Jean-François Formela is a partner and focuses on novel drug discovery approaches and therapeutics. He joined Atlas Venture in 1993 to build the U.S. life sciences franchise.
He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA), Korro Bio, Triplet Therapeutics and Translate Bio (NASDAQ: TBIO). Jean-François also serves on the boards of F-star, Ikena Oncology, Scorpion Therapeutics, and Spero Therapeutics (NASDAQ: SPRO).
His prior investments include Adnexus, ArQule (NASDAQ: ARQL), Arteaus Therapeutics, CoStim Pharmaceuticals, deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL) and NxStage (NASDAQ: NXTM).
Jean-François is a member of the Partners Healthcare Innovation Advisory Board and a former trustee of the Boston Institute of Contemporary Art. He received his M.D. from Paris University School of Medicine and his M.B.A. from Columbia University.
This person is not in any offices
Atlas Venture
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, they have been building breakthrough biotech startups since 1993. They work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Their seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.